1. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE). Issue 5 (16th April 2017) Authors: Drake, Marcus J.; MacDiarmid, Scott; Chapple, Christopher R.; Esen, Adil; Athanasiou, Stavros; Cambronero Santos, Javier; Mitcheson, David; Herschorn, Sender; Siddiqui, Emad; Huang, Moses; Stoelzel, Matthias Journal: International journal of clinical practice Issue: Volume 71:Issue 5(2017) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). (8th June 2017) Authors: Herschorn, Sender; Chapple, Christopher R.; Abrams, Paul; Arlandis, Salvador; Mitcheson, David; Lee, Kyu‐Sung; Ridder, Arwin; Stoelzel, Matthias; Paireddy, Asha; van Maanen, Rob; Robinson, Dudley Journal: BJU international Issue: Volume 120:Number 4(2017) Page Start: 562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mirabegron 50 mg once‐daily for the treatment of symptoms of overactive bladder: An overview of efficacy and tolerability over 12 weeks and 1 year. (4th August 2014) Authors: Chapple, Christopher R; Kaplan, Steven A; Mitcheson, David; Blauwet, Mary Beth; Huang, Moses; Siddiqui, Emad; Khullar, Vik Journal: International journal of urology Issue: Volume 21:Number 10(2014) Page Start: 960 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗